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a b s t r a c t
Coxsackieviruses (CVs) are relatively common viruses associated with a number of serious human
diseases, including myocarditis and meningo-encephalitis. These viruses are considered cytolytic yet can
persist for extended periods of time within certain host tissues requiring evasion from the host immune
response and a greatly reduced rate of replication. A member of Picornaviridae family, CVs have been
historically considered non-enveloped viruses – although recent evidence suggest that CV and other
picornaviruses hijack host membranes and acquire an envelope. Acquisition of an envelope might
provide distinct beneﬁts to CV virions, such as resistance to neutralizing antibodies and efﬁcient nonlytic
viral spread. CV exhibits a unique tropism for progenitor cells in the host which may help to explain the
susceptibility of the young host to infection and the establishment of chronic disease in adults. CVs have
also been shown to exploit autophagy to maximize viral replication and assist in unconventional release
from target cells. In this article, we review recent progress in clarifying virus replication and
dissemination within the host cell, identifying determinants of tropism, and deﬁning strategies utilized
by the virus to evade the host immune response. Also, we will highlight unanswered questions and
provide future perspectives regarding the potential mechanisms of CV pathogenesis.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
Enteroviruses (EVs) are widely distributed in nature and
frequently cause heart and central nervous system (CNS) diseases
(Whitton et al., 2005; Muir and van Loon, 1997). EVs are members
of the Picornaviridae family which include notable members such
as foot-and-mouth disease virus, poliovirus (PV), rhinovirus and
hepatitis A. Some EVs, particularly enterovirus-71 (EV71) in Asia,
are considered to be serious emerging CNS pathogens (Shih et al.,
2011). The EV genus includes an important member, coxsackie-
virus (CV), which cause severe morbidity and mortality in the
newborn and young host (Tebruegge and Curtis, 2009; Romero,
2008). These viruses have a small, positive-sense single stranded
RNA genome, and infection occurs primarily through the fecal–
oral route (Whitton et al., 2005; Feng et al., 2014b). Approximately
15 million diagnosed cases of EV infections occurred in the US in
1996, revealing that EV remains a substantial problematic viral
infection (Sawyer, 2002). The original classiﬁcation of EVs included
the four groups: Coxsackie A viruses, Coxsackie B (CVB) viruses,
ECHO (Enteric Cytopathic Human Orphan) viruses and PVs. A new
classiﬁcation system was devised utilizing consecutive numbers
for each new isolate (such as EV71, EV72, etc.) due to signiﬁcant
overlap between the historically-named EVs (Oberste et al., 2002).
In utero and childhood infection is under-recognized but carries
long-term consequences whereby intellectual and cognitive abil-
ities of the patient might be compromised (Chiriboga-Klein et al.,
1989; Euscher et al., 2001; Chang et al., 2007; Chamberlain et al.,
1983). A relatively common pediatric virus, CV typically causes
mild infections ranging from subclinical to ﬂu-like symptoms and
mild gastroenteritis (Weller et al., 1989). CV has been shown to
infect the heart, pancreas, and CNS (Arnesjo et al., 1976; Rhoades
et al., 2011). In rare cases CVs cause severe systemic inﬂammatory
diseases such meningo-encephalitis, pancreatitis, and myocarditis,
all of which can be fatal or result in lasting organ dysfunction,
including dilated cardiomyopathy and encephalomyelitis (David
et al., 1993; Hyypia et al., 1993). The remarkable distribution of CV
infections can be appreciated by the high seroprevalence in many
countries around the world. In one study, IgG antibodies against
CV were detected in 6.7 to 21.6% of individuals throughout various
regions of Greece (Mavrouli et al., 2007). An analysis of a French-
Canadian population in Montreal showed a seroprevalence as high
as 60–80% for some strains of CV (Payment, 1991). In a region of
China, the seroprevalence for a single serotype of CV was shown to
be greater than 50% in groups aged 15 years or more (Tao et al.,
2013). The wide distribution of CV, their genetic variability, and
ability to persist in the human host make it challenging for
epidemiologists to link previous viral infection and subsequent
pathology, suggesting a potential role for these viruses in chronic
human idiopathies (Victoria et al., 2009) in addition to recognized
illnesses. Vaccine design against CVs and EVs remain challenging
for a number of reasons which include their remarkable genetic
variability and inconsistent pathology in humans.
Spontaneous abortions, fetal myocarditis, and neurodevelop-
mental delays in the newborn remain serious outcomes if CV
infection occurs during pregnancy (Ornoy and Tenenbaum, 2006;
Euscher et al., 2001). Infants infected with CV have a higher
likelihood of developing myocarditis, meningitis and encephalitis;
and the mortality rate may be as high as 10%. Also, many chronic
diseases may be the end result of a previous CV infection. These
chronic diseases include chronic myocarditis (Chapman and Kim,
2008), schizophrenia (Rantakallio et al., 1997), encephalitis lethar-
gica (Cree et al., 2003), and amyotrophic lateral sclerosis (Woodall
et al., 1994; Woodall and Graham, 2004). The molecular mechan-
isms determining the tropism of CVs and their ability to persist in
the host remain unclear. The lasting consequences of CV infection
upon surviving individuals remain largely unknown despite clear
dangers associated with infection and the cytolytic nature of
the virus.
Many publications have suggested a link between early CV
infection and insulin-dependent diabetes (IDDM) (Laitinen et al.,
2014; Jaidane and Hober, 2008; Christen et al., 2012), although
additional data is needed to support these correlative studies. In
addition, a mouse model has shown the development of insulin-
dependent diabetes (IDDM) to be associated with CV-induced
pancreatitis and replication efﬁciency (Drescher et al., 2004),
although the factors determining viral tropism and mechanism
of disease are not well understood (Tracy et al., 2011; Kanno et al.,
2006).
Type B coxsackieviruses (CVB) include six serotypes, each being
associated with acute disease in humans, including acute viral
myocarditis and pancreatitis. While CVB is generally regarded as a
lytic virus, emerging evidence suggests that persistent infection
can be established which may be responsible for chronic inﬂam-
mation within target organs. Moreover, latency and episodic
reactivation could also contribute to the disease process (Feuer
et al., 2002; Ruller et al., 2012; Feuer and Whitton, 2008).
Previously, we described the nature of the CVB viral genome in
quiescent cells whereby a viral state similar to latency was
established (Feuer et al., 2002, 2004). Following stimulation of
quiescent cells by injury, or by the addition of growth factors, viral
protein expression was detected and infectious virus was pro-
duced, suggesting that latent CVB may be reactivated in response
to cellular activation. In parallel, CVB has evolved to modulate cell-
signaling networks to evade host antiviral immunity, enter cells,
and undergo replication even as the host cell suffers the con-
sequences of a cytolytic viral infection (Esfandiarei et al., 2004;
Jensen et al., 2013; Esfandiarei and McManus, 2008).
Our review will cover recent progress speciﬁcally in CVB
research, while acknowledging advances in other areas of EV
investigation which have contributed to a greater understanding
of CVB replication and pathogenesis.
Molecular biology of CVB
CVBs, and EVs in general, are non-enveloped viruses which
have the ability to survive harsh environments. Infection proceeds
via the fecal/oral route, and hence virion stability in the acidic
environment of the stomach becomes a necessity for efﬁcient
transmission. The virion structure exhibits an icosahedral symme-
try with a diameter size of approximately 30 nm (Jiang et al.,
2014). Four capsid proteins (VP1-VP4) comprise the virion struc-
ture, and these viral proteins are major antigenic determinants
following the activation of the host humoral response. The
positive-strand viral RNA genome ranges in size 7 to 8 kb and
is covalently linked at the 50 end with a viral protein called VPg
(the Viral Protein of the genome). VPg, one of the viral proteins 3B,
plays an essential role in both positive and negative-strand RNA
synthesis by covalently attaching to the 50 end of the viral genome
and acting as a primer for RNA synthesis. It remains unclear how
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relatively greater amounts of positive-strand genome are pro-
duced for every negative-strand genome during an EV infection
(Novak and Kirkegaard, 1991). Nevertheless, the ratio of positive-
strand genome to negative-strand genome decreases upon the
establishment of CVB persistence within the CNS (Feuer et al.,
2009; Tam and Messner, 1999). These results suggest that a
double-stranded RNA structure might assist in stabilizing the viral
genome and contributing to persistent infection.
CVB includes several cis-acting RNA elements (CREs) which are
required for efﬁcient viral replication (Steil and Barton, 2009).
CREs contribute to the conversion of VPg into VPgpUpUOH which
acts as a primer for the viral RNA polymerase to initiate replica-
tion. As with other EVs, the CVB RNA genome contains an internal
ribosome entry site (IRES) in the 50 non-translated region (NTR).
CVB RNA lacks a 7-methyl guanosine cap structure, yet host cell
ribosomes can directly interact with the IRES of CVB RNA to
initiate translation of the viral genome (Pelletier and Sonenberg,
1988). The viral genome is translated into a long polyprotein
which undergoes a series of cleavages by the viral proteases 2Apro
and 3CDpro to generate the mature viral proteins. These viral
proteins include VP1-VP4 capsid proteins and seven non-
structural proteins (2A C, 3A D, and 3DPol – RNA polymerase)
(Kitamura et al., 1981). Following viral protein translation,
negative-strand replication begins (Gamarnik and Andino, 1998),
and a viral replication complex forms to produce both positive-
and negative-strand synthesis at the 50 cloverleaf structure of the
50 NTR (Vogt and Andino, 2010). The poly(A) binding protein 1
(PABP1) interacts with the poly(A) tail of the virus leading to
circularization of the viral genome during negative-strand synth-
esis (Herold and Andino, 2001). The virus 2A protein cleaves the
cell protein eIF-4G, a host factor necessary for cap-dependent
translation (Etchison et al., 1982). In this way, CVB maximizes
replication by commandeering nearly all of the available resources
of the host cell. The viral RNA polymerase 3DPol interacts with viral
protein 3AB after attachment to viral membrane vesicles that form
after infection (Fujita et al., 2007).
CVB replication complexes and remodeling of intracellular
membranes
In general, positive strand RNA viruses require cellular mem-
branes for genome replication and actively modify intracellular
membranes to construct their own replication organelles (Belov
and van Kuppeveld, 2012). CVB redirects a number of cell host
factors to remodel intracellular membranes for efﬁcient viral
replication (Wessels et al., 2007; Hsu et al., 2010; Lanke et al.,
2009). These host proteins include phosphatidylinositol-4-kinase
(PI4KIIIβ), guanine nucleotide exchange factor – GBF1, and ARF1
which help to assemble the membrane replication complex
supporting CVB and PV infection (Belov et al., 2007; Lanke et al.,
2009). The current model for the initiation of CVB replication
organelles in the host cell involves the recruitment of PI4KIIIβ
following viral protein 3A binding to GBF1/Arf1 as COPI, a protein
that regulates membrane budding, is displaced. PI4KIIIβ catalyzes
the production of a phosphatidylinositol-4-phosphate (PI4P) lipid
micro-environment leading to the recruitment of viral protein
3Dpol and the synthesis of viral RNA (Hsu et al., 2010). Cholesterol
is actively trafﬁcked from the plasma membrane to viral replica-
tion organelles via clathrin-mediated endocytosis, indicating that
cholesterol modulation is necessary to support elevated viral
replication levels (Ilnytska et al., 2013). The detailed examination
of host proteins and lipids contributing to the formation of viral
replication organelles provides a means of combatting infection by
designing a new class of therapeutic small molecules that target
these host proteins (such as PI4 kinase inhibitors) (Hsu et al.,
2010), or by blocking cholesterol uptake. Nevertheless as with any
antiviral drug candidates, the proclivity of RNA viruses to develop
resistance remains clear (van der Schaar et al., 2012). Also,
antiviral drugs acting on host proteins might be expected to
contribute to cellular anti-proliferative effects and cytotoxicity
(Lamarche et al., 2012). In addition, therapeutic small molecules
shown to reduce viral replication in culture by inhibiting host
proteins may not be as effective in vivo. Recent results have shown
that kinase inhibitors utilized in a murine model of infection may
delay rather than prevent disease, although administration of the
drug was abridged due to toxicity (Ford Siltz et al., 2014).
CVB entry into target cells
Two cell receptors have been identiﬁed which contribute to
CVB entry into target cells. CVB utilizes a transmembrane protein
found within the tight junctions of polarized cells called the
coxsackievirus and adenovirus receptor (CAR) (Bergelson et al.,
1997). Also, human decay accelerating factor (DAF) has been
shown to function as a co-receptor for CVB entry for some viral
isolates (Bergelson et al., 1994). In polarized cells, CVB binds to DAF
at the apical surface of the cell, and binding stimulates intracel-
lular signaling which assists in virion movement across the cell
membrane to the tight junctions (Coyne and Bergelson, 2006).
Subsequently, virion binding to CAR within the tight junctions
leads to CAR-dependent entry in a caveolin-dependent, dynamin-
independent manner. In contrast, CVB entry into non-polarized
cells requires CAR expression in a dynamin-dependent, caveolin-
independent manner (Patel et al., 2009). Although CVB can readily
infect via the intraperitoneal route in mice, the gastrointestinal
route acts as a barrier to infection (Loria et al., 1976). These
ﬁndings illuminate clear differences between the natural human
host, and the murine model of infection. Expression of the human
form of DAF on the intestinal epithelium in transgenic mice failed
to facilitate infection by the enteral route (Pan et al., 2015),
suggesting that other obstacles such as the type I interferon
response (Ohka et al., 2007) and interactions with the intestinal
ﬂora (Kuss et al., 2008) may limit CVB infection in the
murine model.
Receptor expression is necessary for virion entry into possible
target cells (Kallewaard et al., 2009). For example, mice lacking
CAR expression in cardiac tissue completely abolished viral repli-
cation in the heart and prevented myocarditis (Shi et al., 2009).
These results show the in vivo importance of CAR expression for
CVB infection and disease. Also, decreased CAR expression as
primary neurons differentiate in culture correlated with a reduc-
tion in CVB infection (Ahn et al., 2008). The authors concluded that
susceptibility to infection is dependent upon the level of CAR
expression, and changes in CAR expression during development
may limit the number of target cells for CVB. Also, CAR down-
regulation can occur during a carrier-state infection in cells grown
in culture leading to the prevalence of resistant cells over time
(Pinkert et al., 2011). Since CAR is widely expressed in the host yet
distribution of infection is much more limited, additional factors
may ultimately control tropism. For example, CAR expression is
found at high levels in the murine neonatal CNS (Venkatraman
et al., 2005; Honda et al., 2000; Hotta et al., 2003). Yet during early
infection, CVB is largely restricted to neural progenitor cells (NPCs)
or inﬁltrating myeloid cells (Feuer et al., 2005). Preferential
targeting of these cells may be related to their proliferative status
(Feuer et al., 2002, 2003, 2005; Feuer and Whitton, 2008) and
increased autophagic activity (Tabor-Godwin et al., 2012). While
CVB and adenovirus (a DNA virus) both utilize the identical host
receptor (CAR), the tropism for each virus appear quite distinct
in vivo – indicating other factors at play, such as the tissue-speciﬁc
J. Sin et al. / Virology 484 (2015) 288–304290
type I interferon response, in controlling tissue tropism (Wessely
et al., 2001).
The role of autophagy during CVB replication
Autophagy is a process by which cells breaks down long-lived,
decaying, or damaged organelles and proteins. Several investiga-
tors have identiﬁed autophagy as a crucial component for the
replication and survival of various EVs – including CVB which
subverts host autophagy upon infection (Alirezaei et al., 2012a).
This view is demonstrated in the host by a report showing reduced
pancreatic pathology and lower viral titers in mice lacking ATG5
expression in the pancreas after CVB infection (Alirezaei et al.,
2012b). Autophagy is initiated with the activation of class III
phosphatidylinositol 3 kinase (PtdIns3K) signaling. PtdIns3K sig-
naling allows for the nucleation of the phagophore – a cup-shaped
double membrane which elongates around cellular components to
be degraded. The phagophore structure is commonly believed to
originate from the endoplasmic reticulum (ER) (Hamasaki et al.,
2013). ATG4 truncates microtubule-associated protein 1A/1B-light
chain 3 (LC3-I) to expose the C-terminal glycine which becomes
conjugated to phophatidylethanolamine to form LC3-II. LC3-II is
then recruited to the elongating phagophore, and because of this,
LC3-II is a common marker used in the detection of autophagy via
western blot and immunostaining (Gustafsson and Gottlieb, 2008;
Klionsky et al., 2012). Once the autophagosome is complete, the
structure fuses with a lysosome to form the autolysosome, and the
cargo within are degraded by acidic hydrolases.
Previous work has shown that several EVs such as PV, CVB and
EV71 trigger autophagy and hijack the autophagosomal mem-
branes to enhance viral replication (Suhy et al., 2000; Wong et al.,
2008a; Huang et al., 2009). Also, cell host factors which sup-
pressed autophagy inhibited CVB replication (Delorme-Axford
et al., 2014). PV proteins 3A and 2BC had been shown to elongate
the ER and induce autophagosome formation, respectively. Many
viruses have been thought to assemble replication factories onto
autophagosomal membranes in order to enhance replication
efﬁciency (Wileman, 2006). With that in mind, CVB has been
shown to prevent autophagic ﬂux causing virus-ﬁlled autophago-
somes to accumulate and merge into “megaphagosomes” (Kemball
et al., 2010a). Additionally, the induction of autophagy may allow
for non-cytolytic escape of EVs from the host cell (Taylor and
Kirkegaard, 2008; Bird et al., 2014).
Autophagy is crucial for maintaining cellular homeostasis and
has been shown to prevent cellular damage in the CNS following
activation via short-term fasting (Simonsen et al., 2008; Alirezaei
et al., 2010). The induction of autophagy in rat primary neurons
was associated with increased CVB replication (Yoon et al., 2008).
Curiously, an inverse correlation between autophagy and apopto-
sis was observed when rat primary neurons were infected with
CVB4 (Yoon et al., 2009). Therefore, deciphering the role of
autophagy during the progression of CVB infection in rapidly
cycling cells/progenitor cells and during establishment of viral
persistence in the heart and CNS may be critical in controlling
disease.
CVB is capable of subverting host autophagy via 2A protease
which cleaves sequestosome 1 (SQSTM1)/p62 (Shi et al., 2013).
This protein serves in trafﬁcking ubiquitinated proteins to the
autophagosome by joining with LC3-II. The disruption of SQSTM1
results in impaired selective autophagy and allows CVB to circum-
vent host defense signaling. However, CVB has also been shown to
become actively trafﬁcked into autophagosomes possibly to pro-
mote viral dissemination via the release of intracellular vesicles.
How and why CVB prevents general cargo uptake of cellular
components in autophagosomes while still allowing its own
engulfment is unclear, but these processes may vary based on
speciﬁc cell types and environmental conditions. Autophagy
inhibitors have been shown to decrease extracellular compared
to intracellular poliovirus titers (Jackson et al., 2005a). Hence,
modulation of autophagy by candidate drugs might function as
therapeutic antivirals during acute or persistent CVB infection.
CVB infection of neural progenitor cells (NPCs)
Previously, we generated a pediatric model of CVB infection in
the CNS and heart in order to study virus tropism and disease
(Feuer et al., 2003, 2005, 2009). We demonstrated the ability of
CVB to target neural progenitor cells (NPCs) within the neonatal
CNS (Feuer et al., 2003), or grown in culture as neurospheres
(Tsueng et al., 2011; Rhoades et al., 2011). Neurospheres, or free-
ﬂoating spheres generated by NPCs in culture, can be differen-
tiated into neurons, astrocytes, and oligodendrocytes (Eriksson
et al., 2003). NPCs were highly susceptible to infection, and
cytopathic effects were readily observed following infection. In
contrast, differentiated NPCs were less susceptible to CVB infec-
tion. We suggested that the reduced susceptibility to CVB infection
was due to their decreased proliferative status and cellular
changes associated with differentiation (Feuer et al., 2002). Deple-
tion of NPCs by virus-mediated apoptosis led to CNS develop-
mental defects in the host (Ruller et al., 2012), and CVB could
establish a persistent infection causing chronic inﬂammation in
the brain (Feuer et al., 2009). We hypothesized that progenitor
cells may survive initial infection and contribute to virus persis-
tence, either indirectly (contributing to virus attenuation) or
directly (progenitor cells harboring viral materials) (Rhoades et
al., 2011).
The process of autophagy is thought to be critical for stem cell
maintenance and during cell lineage commitment (Guan et al.,
2013; Vessoni et al., 2012). The role of autophagy during CVB
infection was shown to be cell-speciﬁc, and NPCs supported
greater levels of viral infection (Tabor-Godwin et al., 2012). As
previous demonstrated by other groups utilizing transformed cell
lines (Wong et al., 2008b), HL-1 cells (a transformed cardiomyo-
cyte cell line) showed an increase in autophagic signaling follow-
ing infection with CVB; viral titers increased after autophagy
induction and decreased after autophagy inhibition. In contrast,
no change in autophagic signaling was seen in NPCs following
infection, although basal levels of autophagy were higher com-
pared to HL-1 cells. Furthermore, higher levels of autophagy
signaling could be induced in NPCs without increasing viral
replication levels. In differentiated NPC precursors, autophagy
increased during differentiation. Unexpectedly, a decrease in
autophagy was observed in neurons, astrocytes, and oligodendro-
cytes following CVB infection. These observations were quite
surprising since picornaviruses have been shown to consistently
activate autophagy during infection (Kirkegaard, 2009), and autop-
hagosomes may be required for optimal picornaviral replication
(Taylor and Kirkegaard, 2008).
CVB might be expected to target NPCs for a variety of reasons.
The naturally high basal levels of autophagic activity in NPCs may
explain their relatively greater susceptibility to CVB infection.
NPCs normally undergo rapid expansion and proliferation during
development and regeneration of tissue, and CVB has been shown
to preferentially replicate in cells undergoing active proliferation
(Feuer et al., 2002, 2005). As NPCs differentiate into neurons, these
cells migrate into regions of the hippocampus and the olfactory
bulb. Migration of infected NPCs would be expected to assist in
virus dissemination, and the olfactory bulb could provide an
escape route for the virus through the olfactory neuroepithelium.
We hypothesize that viral infection might alter NPCs and neurons
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derived from infected NPCs, leading to possible behavioral mod-
iﬁcations within the host in order to maximize virus transmission.
Also, quiescent NPCs may harbor persistent/latent infection until a
later point in time when active neurogenesis stimulates virus
reactivation (Rhoades et al., 2011). Finally, immune-privileged
regions such as the CNS could limit antiviral responses against
CVB providing for a fruitful and protected area of viral replication.
Utilization of recombinant CVBs expressing foreign proteins
A number of research groups have generated recombinant CVBs
(rCVBs) expressing molecular markers, cytokines, and other for-
eign proteins (Slifka et al., 2001; Feuer et al., 2002; Henke et al.,
2001). Many of these recombinant viral constructs have proven to
be quite stable, although the loss of the foreign insert can appear
Fig. 1. HeLa cells infected with Timer-CVB slowly change ﬂuorescence from green to red. The gene for “ﬂuorescent timer” protein was inserted into the infectious plasmid
clone for CVB. (A) Upon infection with recombinant CVB3 expressing “ﬂuorescent timer” protein (Timer-CVB), the slow conversion of the green ﬂuorescing form of timer
protein to red occurred over time in cells overlaid with agar. Initial sites of infection ﬂuoresced red, while newly infected cells ﬂuoresced green. (B) HeLa cells infected with
Timer-CVB (moi¼0.1) initially ﬂuoresced green (recent viral protein) at 24 h PI as determined by ﬂuorescence microscopy. By 32 h PI, both green and red ﬂuorescence
(matured viral protein) was observed in infected HeLa cells, and by 48 h PI the majority of cells ﬂuoresced brightly in the red channel. Fewer green and red infected cells
were observed by ﬂuorescence microscopy for HeLa cells treated with the antiviral drug ribavirin (100 mg/ml) at every time point.
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in the viral population within ﬁve passages, depending upon the
size of the insert, nucleotide sequence, nature of the gene, and
passage conditions. The utilization of these rCVBs in tissue culture
and in vivo have clariﬁed questions regarding viral tropism (Feuer
et al., 2005; Puccini et al., 2014), activation of the adaptive immune
response against infection (Kemball et al., 2009), mechanisms of
virulence and disease (Zeng et al., 2013), and possible uses of CVB
as therapeutic/vaccine vectors (Kim et al., 2012; Miller et al.,
2009).
The importance of following viral infection temporally using
minimally invasive and real time tools may lead better under-
standing of CVB pathogenesis. Temporal studies for other viruses
have demonstrated the role of efﬁcient viral dissemination in
enhancing virus replication. For example, vaccinia virus maximizes
viral spread by targeting uninfected cells rather than re-infecting
nearby cells (Doceul et al., 2010). A different strategy is utilized by
human T-lymphotropic virus-1 (HTLV-1) which creates a specia-
lized area of cell-cell contact – the virological synapse – promoting
transmission of virus between cells (Nejmeddine and Bangham,
2010). To inspect the progression of CVB dissemination, we
designed a unique rCVB expressing “ﬂuorescent timer” protein
(Timer-CVB) to track virus spread in cells grown in culture, and
within our animal model of infection (Robinson et al., 2014).
“Fluorescent timer” protein (Terskikh et al., 2000) is converted
from green ﬂuorescence to red ﬂuorescence over a period of
48 h which allows viral spread to be observed in real time based
on color changes (Fig. 1). By standard plaque assay, Timer-CVB
plaques demonstrated a “bull's-eye” pattern by ﬂuorescence
microscopy whereby initial infection was represented by red
ﬂuorescence and newly-infected cells via cell-to-cell spread were
revealed by green ﬂuorescence. Timer-CVB3 may be of particular
beneﬁt in evaluating antiviral compounds in target cells and
deciphering their mode of action. For example, antiviral com-
pounds which inhibit the release of infectious virus from the host
cell would be represented by infected green cells, followed by
yellow, and ﬁnally red cells with no new green cells being
observed. In contrast, antiviral compounds acting to simply reduce
the level of infectious virus production would show new green
cells, although at a lower level compared to untreated cultures.
The use of Timer-CVB revealed fascinating aspects of virus
replication that we did not expect. First by creating time-lapse
videos, we identiﬁed extensive intracellular membrane remodel-
ing in infected progenitor cells (Robinson et al., 2014) reminiscent
of viral replication organelles previously described by other
research groups (Hsu et al., 2010). These time lapse videos showed
viral replication organelles ﬂuorescing in an asynchronous fashion
and revealed the dynamics of intracellular membrane reorganiza-
tion following infection. “Fluorescent timer” protein and viral 3A
protein colocalized closely, suggesting that the molecular marker
remained trapped within viral replication organelles shortly after
translation. Viral 3A protein can bind and modulate host cell
factors such as PI4KIIIβ, GBF1 and ARF1, and facilitate intracellular
membrane remodeling for efﬁcient viral replication (Wessels et al.,
2007; Hsu et al., 2010; Lanke et al., 2009). Along with participation
in the formation of viral replication organelles, viral 3A protein
was previously shown to halt protein trafﬁcking and secretion by
disrupting the Golgi apparatus (de Jong et al., 2006; Cornell et al.,
2006, 2007). We expect that Timer-CVB may be of value in
identifying the formation of viral replication organelles in real
time within the cell, and for tracking viral spread in our animal
model of infection.
CVB escapes the host cell through ejected autophagosomes
As a non-enveloped, protein encapsulated virus, EVs such as
CVB have classically been thought to escape the infected host via
cytolysis whereby released virions would rapidly be exposed to
host neutralizing antibodies. Interestingly, we observed extracel-
lular microvesicles (EMVs) containing infectious virus released
from various progenitor cell types infected with Timer-CVB
(Robinson et al., 2014) (Fig. 2). Upon further analysis, these
Fig. 2. Detection of LC3 and CVB viral protein in shed EMVs Differentiated NPSCs transduced with adeno-LC3-GFP were infected with dsRED-CVB (moi¼0.1) and observed by
ﬂuorescence microscopy at 3 days PI. (A) Abundant shed EMVs (white arrows) expressing viral protein (red) and a marker for autophagosomes (LC3-GFP, green) were readily
observed. (E–F) Higher magniﬁcation of (C) showed colocalization of viral protein and LC3-GFP in shed EMVs.
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structures were shown to be enriched with LC3-II, a common
marker for autophagosomes. The presence of LC3-II in virally-
induced EMVs, and the lack of LC3-II in basally-released exosomes
from uninfected cells suggest that CVB may be actively trafﬁcked
into autophagosomes which subsequently promotes their release
from the cell. This model would be akin to the previously-
described phenomenon of autophagosome-mediated exit without
lysis (AWOL) following PV infection (Taylor et al., 2009; Richards
and Jackson, 2012). Whereas CVB appeared to escape the cell
bound in intact membranes, in the case of PV infection, these
microvesicles were hypothesized to be unstable although contri-
buting to the release of viral particles from the host cell in the
absence cell lysis. Our results suggest that CVB coordinates a
unique method of viral dissemination by utilizing the autophagy
pathway, and that these EMVs may be more stable that previously
proposed. CVB had been shown to increase the accumulation of
autophagosomes in the pancreata of infected mice wherein
autophagosomes fused into megaphagosomes (Kemball et al.,
2010a). We previously documented a reduction of autophago-
somes in the cytoplasm of partially differentiated NPCs infected
with CVB; however upon closer inspection, numerous EMVs
appeared to be budding from the surface of these infected cells,
possibly as a result of intracellular autophagosomes being expelled
into the extracellular space (Tabor-Godwin et al., 2012). More
recently, PV, CVB, and rhinovirus particles were shown to be
released within phosphatidylserine vesicles by host cells in a
non-lytic fashion (Chen et al., 2015). Multiple viral particles were
observed within individual vesicles, which may provide for
cooperation among viral quasispecies and lead to more efﬁcient
infection compared to free viral particles.
The utilization of EMVs could promote viral dissemination and
infection in a number of ways (Fig. 3). Because EMV-mediated
virus dissemination allows CVB to be membrane-bound, this
method of release could potentially broaden the range of suscep-
tible target cells by bypassing canonical receptor-mediated endo-
cytosis, and instead fusing with cells that may lack CAR or DAF.
Notwithstanding this possibility, CAR expression in some target
tissues such as the heart remains a critical determinant of tropism
and eventual disease progression (Shi et al., 2009). Yet, EMVs
might still contribute to infection of other cells or tissues prior to
eventual dissemination into the heart, or during the establishment
virus persistence within cardiac tissue. For example, CVB was
shown to efﬁciently infect and utilize B lymphocytes for dissemi-
nation despite barely detectable levels of CAR expression on these
important target cells (Mena et al., 1999). Because exit via EMVs
provide a non-cytolytic method for CVB escape, this mechanism
could potentially prolong viral replication in the host cell. EMVs
could also enhance viral stability in the extracellular space as well
as mask the virus from host neutralizing antibodies (Inal and Jorﬁ,
2013; Masciopinto et al., 2004). Though intact virions were
observed in EMVs observed under electron microscopy
(Robinson et al., 2014), these structures could presumably contain
free viral RNA and still remain infectious. This would allow CVB to
infect cells during persistence (Feuer et al., 2009) without the need
to assemble viral capsids or induce cellular cytopathicity (Taylor
et al., 2009; Bird et al., 2014). This novel route of dissemination
Fig. 3. Model of CVB dissemination in the host by shed EMVs. High numbers of LC3IIþ extracellular microvesicles (EMVs) containing infectious virus were recently observed
following infection of progenitor cells in culture. Both the differentiation process and viral infection may enhance shedding of single membrane EMVs derived from the
autophagy pathway. (A) Virus-associated EMVs may expand the natural tropism of CV to target cells which fail to express canonical virus receptors. (B) Neutralizing
antibodies may be ineffective against infectious virus sequestered within the protected environment of the extracellular microvesicle. Also, virus-associated EMVs may
increase the stability of infectious virus within the host during hematogenous spread. (C) EMVs may assist in viral RNA dissemination during the persistent stage of infection
whereby the presence of intact virions and/or structural viral proteins may be limited. (D) EMVs may help virions travel and enter new target tissues and cross selectively
permeable barriers.
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would be analogous to RNA-containing exosomes, a process
whereby host RNAs and micro-RNAs are transported for cell-to-
cell communication purposes (Meckes and Raab-Traub, 2011; Gallo
et al., 2012; Delorme-Axford et al., 2013).
CVB has been shown to preferentially target numerous progenitor-
like cells such as NPCs and cardiac progenitor cells (CPCs). Because
these types of cells often mobilize to areas of needed tissue repair once
activated, CVB may be able to “hitchhike” within these cells to access
new tissues that the virus would normally be unable to penetrate.
Similarly, EMVs may allow CVB to enter selectively permeable tissues
such as the CNS by bypassing the blood-brain-barrier or blood-CSF-
barrier (Sampey et al., 2014). Despite this, host defense mechanisms
appear to have co-evolved in response to the release of virus-
associated EMVs. Exosome-bound hepatitis C RNA has been shown
to activate plasmacytoid dendritic cells, conferring protective innate
immunity in the host (Dreux et al., 2012). Additionally, phagocytic
immune cells such as macrophages recognize speciﬁc “eat me”
markers which may decorate CVB-associated EMVs and target them
for degradation (Miyanishi et al., 2007).
The recent discovery of membrane-stealing picornaviruses,
which now include hepatitis A (Feng et al., 2013), might point to
a two-fold strategy for a family of viruses that can leave the host as
a non-enveloped virion, as well as maintain a cloaked, enveloped
form – at least after infection of certain host cells. Why might a
virus utilize this dual strategy? Perhaps some picornaviruses
preserve this duality in order to maximize stability in different
environments (Feng and Lemon, 2014). For example, a non-
enveloped form of virus may have of greater stability in an
inhospitably dry or hypotonic environment. In contrast, an envel-
oped form of virus may be more advantageous for hematogenic
dissemination in the host where circulating neutralizing antibo-
dies might otherwise neutralize virions with exposed antigenic
proteins.
“Bus Stop/Trojan Horse” model for CVB entry across the tight
junctions
One of the paradoxes regarding receptor usage by a large
number of viruses, including CVB, is their dependence upon
receptors located in seemingly inaccessible tight junctions of
polarized epithelial cells (Bergelson, 2009; Delorme-Axford and
Coyne, 2011). For many viruses including CVB, the epithelial cell
layer may be the ﬁrst barrier encountered for entry into the host.
Although polarized epithelial cells grown in culture have been
utilized to model CVB entry into target cells (Coyne and Bergelson,
2006; Coyne et al., 2007), these cells do not appear to support high
levels of CVB replication and virus protein expression in vivo –
despite their expression of CAR. Instead, acinar cells of the
pancreas, cardiomyocytes, bone marrow and activated lympho-
cytes within the marginal regions of the spleen, inﬁltrating
nestinþ myeloid cells, progenitor cells in juvenile mice, and
immature neurons of the CNS are the major targets of CVB
infection in the host.
We suggest that virus binding to intrajunctional proteins might
represent a common strategy for viruses to target migratory cells
traveling through tight junctions of several tissues (Fig. 4). For
example, we previously showed that CVB infected nestinþ mye-
loid cells which entered through the tight junctions of the choroid
plexus epithelial cells (Tabor-Godwin et al., 2010). The choroid
plexus forms the blood-CSF-barrier in the CNS, and entry of
activated immune cells is controlled by the tight junctions of the
choroid plexus cuboidal epithelium (Ransohoff et al., 2003). The
choroid plexus regulates CSF production, and transthyretin (TTR), a
hormone binding protein, is actively transported by the choroid
plexus into the CSF (Dickson et al., 1986). The choroid plexus also
performs unique host functions (Emerich et al., 2005), including
secretion of growth factors (Shingo et al., 2003) and participation
Fig. 4. “Bus Stop/Trojan Horse” model for CVB entry across the tight junctions of the blood–CSF barrier. We propose that CVB initially binds to CAR, a tight junction protein,
although not entering epithelial cells of the choroid plexus. Upon binding, CCL12 and other chemokines are released by epithelial cells thereby attracting nestinþ myeloid
cells which undergo extravasation through tight junctions of choroid plexus epithelial cells. CVB virions enter nestinþ myeloid cells which support infection, and assist with
virus entry into the CNS.
J. Sin et al. / Virology 484 (2015) 288–304 295
in neurogenesis (Falk and Frisen, 2002). The recruitment of these
novel myeloid cells was preceded by the induction of CCL12, a
chemokine known to attract monocytic cells (Saraﬁ et al., 1997)
and ﬁbrocytes (Moore et al., 2006). Although epithelial cells
appeared spared from infection, CVB induced signiﬁcant acute
damage in the choroid plexus (Puccini et al., 2014). Also, infected
nestinþ myeloid cells were shown to migrate into the CNS and
assist in virus dissemination.
Why might CVB target intrajunctional proteins sequestered
within highly inaccessible areas of epithelial cells? We propose
that CVB, and other viruses, attach to intrajunctional proteins in
order to “hitch-hike” on migratory immune cells responding to
early infection. The utilization of immune cells for virus spread
into primary target organs has been previously described by others
(Mena et al., 1999; Noda et al., 2006). Infected immune cells might
shield the virus from neutralizing antibodies upon migration into
secondary tissues. This strategy may not be unique to CVB,
although the particular intrajunctional protein utilized by each
virus may be distinct (Bergelson, 2009). Other virus families may
have evolved to follow a similar method of dispersion via immune
target cell “Trojan horses”, although perhaps utilizing a unique
signature chemokine proﬁle and matching responding
immune cells.
CVB infection of cardiac progenitor cells (CPCs) and
pathological remodeling of the heart
Though the frequency of CVB exposure in the population is
difﬁcult to estimate due to its often asymptomatic nature, an
epidemiological study by Petitjean et al. found that 39.1% of
healthy individuals harbor enteroviral RNA (Petitjean et al.,
1992). These data highlight the prevalence of CVB infections which
go undetected; however of equal concern was the detection of
enteroviral RNA in 66.7% of patients with idiopathic dilated
cardiomyopathy. Though a link between acute myocarditis and
dilated cardiomyopathy is well-documented (Satoh et al., 1994;
Mason, 2002; Kearney et al., 2001; Cheng, 2006), a causal relation-
ship between mild subclinical infection and subsequent dilated
cardiomyopathy – such as in the case of idiopathic cardiomyo-
pathy – is less understood.
Our group has recently published a study which may shed light
on the association between mild acute infection and late onset
heart failure (Sin et al., 2014). We developed a juvenile mouse
model of mild CVB infection in which viral RNA and infectious
particles could be detected at a high level in the heart immediately
following infection, and both c-kitþ and Sca-1þ cardiac progenitor
cells (CPCs) were preferential target cells for infection in the heart
(Fig. 5). Sca-1þ cells in the hearts of infected mice were shown to
co-express mature vascular cell markers such as von Willebrand
factor (endothelial) and SM22 (smooth muscle). Viral clearance
occurred prior to the adult phase, and both mock and CVB-infected
animals appeared healthy, suckled normally, and grew at similar
rates. Heart weights were normal, and cardiac inﬂammation could
not be detected by hematoxylin and eosin staining up to 11 weeks
post-infection. Nevertheless, staining for c-kit antigen in heart
sections revealed a 50% reduction in this progenitor cell popula-
tion at 11 weeks post-infection. After CVB exposure, CPCs showed
a strong predisposition to differentiate into vascular cells. CVB has
been previously shown to upregulate autophagy, a process which
may be essential during cell differentiation (Guan et al., 2013).
Hence in addition to targeting CPCs for infection, CVB may drive
their premature differentiation and impair their capacity for self-
renewal. This effect ultimately may result in the depletion of the
CPC pool seen in juvenile-infected adult mice, in addition to any
cytolytic effects.
What does a compromised CPC population mean for the adult
heart? Adult mice given a low inoculum of CVB during the juvenile
period appeared healthy and indistinguishable from the mock-
infected control mice. Indeed, cardiac hypertrophy and dilation
indicative of progression to heart failure was observed only when
these juvenile-infected adult mice were subjected to exercise or
pharmacologically-induced cardiac stress. Infected animals
showed evidence of cardiac hypertrophy and myocardial scarring
following swimming exercise or isoproterenol treatment. Further
investigation revealed that mock-infected animals were able to
augment blood vessel formation following increased cardiac load,
whereas CVB-infected animals could not perform this type of
vascular remodeling. Stem cells are intimately involved in angio-
genesis and neovascularization via paracrine signaling and direct
differentiation (Huang et al., 2010; Lu et al., 2013; Leeper et al.,
2010). We hypothesize that the diminished CPC population in the
CVB-infected heart resulted in impaired adaptive vascular remo-
deling. This impairment in vascular remodeling does not allow for
proper perfusion of the myocardium under load, leaving the
muscle ischemic and triggering pathological hypertrophy and
cardiac damage (Fig. 6).
Targeting of CPCs by CVB is not entirely unexpected based on
the known susceptibility of progenitor cells to infection (Feuer
et al., 2005, 2002; Feuer and Whitton, 2008; Willcox et al., 2011).
CVB may show preferential tropism for progenitor cells, and
infection may alter cell lineage commitment or diminish their
restorative capacity (Feuer et al., 2003, 2005; Tabor-Godwin et al.,
2012; Feuer and Whitton, 2008; Rhoades et al., 2011; Ruller et al.,
2012; Tsueng et al., 2011; Althof and Whitton, 2012). Infection of
progenitor cells may also lead to augmented virus dispersal via
autophagosome-mediated exit without lysis (AWOL) (Robinson et
al., 2014; Jackson et al., 2005b). Given that the heart is comprised
primarily of post-mitotic myocytes, a pool of cycling CPCs would
provide optimal targets for infection. The ultimate fate of infected
progenitor cells is unknown, although infection caused premature
differentiation of CPCs towards a vascular lineage.
Escape from the innate antiviral immune response
CVBs and other EVs have evolved many unique mechanisms to
evade the host immune response (Harris and Coyne, 2013; Feng
et al., 2014b; Kemball et al., 2010b). For example, CVB viral
Fig. 5. CVB productively infected progenitor cells in the juvenile heart. Three day-
old mice were infected with eGFP-CVB (105 pfu IP) or mock-infected, and hearts
were isolated at 2 days PI. Parafﬁn-embedded sections of heart tissue were
deparafﬁnized and stained using an antibody against Sca-1 (green) and virus
protein (red). Many Sca-1þ cells in heart tissue were shown to be infected with
eGFP-CVB. DAPI (blue) was utilized to label cell nuclei. Representative images of
three infected mice are shown.
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proteases which include 3C and 2A proteinases have been shown
to attenuate the Type I IFN response by cleaving focal adhesion
kinase, MDA5, RIG-1, and MAVS host proteins (Bozym et al., 2012;
Mukherjee et al., 2011; Feng et al., 2014a). A common feature
following any infection of the host cell includes the induction of
the stress response which acts against viral infection by inhibiting
protein synthesis (Lloyd, 2012). Viral infection can trigger stress
granules (SG) which comprise translationally silenced messenger
ribonucleoproteins thereby inhibiting the viral genome from being
translated (Onomoto et al., 2014; Lloyd, 2013). Poliovirus 3C
proteinase can cleave RasGAP-SH3-binding protein (G3BP), a
necessary component of SG formation (Reineke and Lloyd, 2015).
CVB, similar to poliovirus, disrupted processing bodies (P bodies)
involved in decapping, decay, and translational silencing of mRNA
(Dougherty et al., 2011). P bodies contain Xrn1, Dcp1a, and Pan3
proteins which play a role in 50-end mRNA decapping and
degradation. These proteins were found to be degraded in target
cells following infection with CVB. The degradation of key compo-
nents of P bodies may provide a mechanism for CVB to replicate to
high levels in the host cell despite the initiation of the stress
response following infection.
CVB also can antagonize the apoptotic pathway in cells, allow-
ing viral replication to proceed for a longer amount of time
necessary to maximize progeny (Harris and Coyne, 2014). For
example, CVB can cleave cell components of the pro-apoptotic
family, including TRIF (Mukherjee et al., 2011), and viral 2B protein
can act as viroporin disrupting Ca2þ gradients necessary to initiate
apoptosis (Campanella et al., 2004). Evasion of the host antiviral
response maximizes viral replication during acute infection and
may also be critical for the establishment of viral persistence.
Recently, in vivo ablation of type I interferon receptor in cardio-
myocytes was shown to accelerate myocarditis, although infection
in cardiac tissue remained highly focal (Althof et al., 2014). These
results indicate that other unidentiﬁed antiviral factors may
prevent more widespread dissemination within the heart.
A recent study has clariﬁed the role of matrix metalloproteinase-12
(MMP-12) in antiviral immunity (Marchant et al., 2014) against CVB.
Although interferon-α (IFN-α) is essential for antiviral immunity,
activated iκBα (encoded by NFKBIA) is necessary for the export of
IFN-α from virus-infected cells. MMP-12 mediates NFKBIA transcrip-
tion which induces IFN-α secretion and protection from CVB infection.
Simultaneously, MMP-12 limits the antiviral immune response by
cleaving the IFN-α receptor 2 binding site. However, a membrane-
impermeable MMP-12 inhibitor was shown to increase IFN-α levels
and reduce CVB titers in the pancreas. These studies suggest that
modulation of the antiviral response with inhibitors against MMP-12
may assist in controlling CVB infection in the host.
Few studies have inspected the ability of progenitor cells to
mount effective antiviral responses and be protected from micro-
bial infection. Utilizing our in vivo model of CNS infection, unique
host immune gene expression changes were observed for CVB
compared to a different neurotropic virus – LCMV – an arenavirus
considered to activate the prototypical immune response in the
host (Puccini et al., 2014). CCL12, CCL7, CCL4, CXCL4, and CCL2
were upregulated at early time points following CVB infection. In
contrast, MHC class I gene expression, several developmental-
related Hox genes, and TTR were speciﬁcally downregulated after
CVB infection. Intriguingly, toll-like receptors have been found to
Fig. 6. Model of adult heart failure in juvenile CVB-infected mice (A) A population of CPCs susceptible to CVB infection resides within the myocardium. Upon augmented
cardiac stress, oxygen demand increases within the heart tissue. CPCs are recruited to drive angiogenesis and neovascularization which increases vascular density in the
muscle allowing for efﬁcient perfusion of oxygenated blood. (B) When the heart undergoes mild CVB infection, CPCs are preferentially targeted by the virus resulting in a
depletion of the CPC population; however the myocardium is otherwise normal. Following cardiac stress, the limited number of remaining CPCs cannot sufﬁciently stimulate
blood vessel formation and the myocardium becomes ischemic. The lack of vascularization causes the heart to become hypertrophic resulting in scar formation and cardiac
dysfunction.
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modulate adult hippocampal neurogenesis via MyD88 activation
(Rolls et al., 2007), and CVB infection in the developing CNS might
alter normal development both by targeting progenitor cells
(Ruller et al., 2012), and by inducing a local inﬂammatory antiviral
response.
Adaptive immune response following CVB infection
The signiﬁcant contribution of a neutralizing antibody response
in controlling EV infections can be seen in reports of individuals
suffering from agammaglobulimia who develop chronic neuropa-
thies following CVB infection (Misbah et al., 1992). Antibodies
were shown to be vital for clearing infectious virus in mice lacking
B cells (Mena et al., 1999). B cells also contribute to virus
dissemination via the “Trojan horse” dissemination. High levels
of viral RNA were observed within the marginal zone of the spleen
suggesting active infection of proliferating lymphocytes. Activated
microglia and macrophages also contribute to the host response
against infection by actively engulfed virally-infected cells (Feuer
et al., 2009).
Activation of the T cell response in the host may be dependent
on the EV genus (Slifka et al., 2001). Although T cells are critical to
controlling viral infections, CVB has evolved numerous strategies
to escape CD8þ T cells, for example, by inhibiting MHC class I
antigen presentation (Kemball et al., 2009). CVB has also been
shown to alter the stimulatory capacity of dendritic cells which
may impair the host's ability to induce protective antiviral T cell
responses (Kemball et al., 2012). Also, CVB can infect the bone
marrow and erythroid and lymphoid progenitor cell populations,
further impacting host immune responses (Althof and Whitton,
2012).
CVB vaccines and antiviral candidates
Many researchers have developed effective vaccines against
CVB using various vaccines strategies including DNA plasmids
expressing viral proteins, inactivated virus, or live attenuated
forms of virus – although no clinically available vaccine currently
exists. A safe and effective vaccine based on RNA was shown to
protect mice against virus challenge, although no neutralizing
antibodies were detected (Hunziker et al., 2004). RNA-based
vaccines may be safer than DNA vaccines due to their inability to
integrate into cellular DNA. Attenuated viruses have also been
shown to be protective against lethal re-challenge in mice (Dan
and Chantler, 2005). Recombinant plasmids expressing capsid
proteins following in vivo electroporation can induce protective
virus-speciﬁc antibodies (Park et al., 2009). Novel virus receptor
traps have been designed based on soluble virus receptor fusion
proteins which were able to reduce myocardial inﬂammation,
ﬁbrosis, and viral titers in CVB-infected mice (Lim et al., 2006).
Neonatal patients infected with EVs have been treated with
immunoglobulin, although few studies have shown clinical efﬁ-
cacy which remains controversial based on low antibody titers and
intratypic variation against particular serotypes circulating within
a community (Abzug, 2004; Galama et al., 1997). The method of
immunoglobulin preparation involves pooling plasma products
from normal donors (Cheng et al., 2008), and non-speciﬁc anti-
inﬂammatory, yet protective responses may be induced following
intravenous immunoglobulin treatment (Ooi et al., 2010).
RNA interference (RNAi)-based strategies have been used to
limit CVB replication in culture, and in vivo. The potential to utilize
RNAi as an effective antiviral drug against RNA viruses was ﬁrst
shown in 2003 (Gitlin and Andino, 2003). RNAi-based immunity
against viral infection is dependent upon Dicer recognition of the
viral dsRNA formed during viral replication (Aliyari and Ding,
2009). Small interfering RNAs (siRNAs) directed against protease
2A were shown to inhibit CVB infection in HeLa cells and murine
cardiomyocytes (Yuan et al., 2005). siRNA molecules designed to
target the CVB viral 2A region successfully reduced viral titers and
prolonged survival in susceptible mice (Merl et al., 2005). Also,
siRNA molecules designed to target the viral 3CPro region of CVB
reduced viral replication without showing signs of toxicity (Tan
et al., 2010). Based on the ability of RNA viruses to quickly evolve
and become resistant to siRNA molecules, other researchers have
combined three different antiviral siRNA molecules to limit the
appearance of CVB escape mutants (Merl and Wessely, 2007). In
contrast, targeting host host-speciﬁc proteins may circumvent the
appearance of CVB escape mutants yet reduce viral replication, for
example, in cells treated with CAR-speciﬁc siRNA molecules (Werk
et al., 2005).
Ribavirin (1-(_-d-ribofuranosyl)-1H-1,2,4-triazole-3-carboxa-
mide) is a broad-spectrum antiviral compound initially proposed
as a nucleoside inhibitor, although more recently shown to work
by acting as a mutagen and inducing ‘error catastrophe’ during EV
replication (Crotty et al., 2000, 2001; Crotty and Andino, 2002;
Vignuzzi et al., 2006). We have shown previously that ribavirin
could improve brain wet weight recovery during persistent infec-
tion in the CNS (Ruller et al., 2012). Pleconaril,3-(3,5-dimethyl-4
((3-(3-methyl-5-isoxazolyl)propyl]oly)phenyl)-5-(triﬂuoro-
methyl)-1,2,4-oxadiazole was originally developed as an anti-
picornaviral drug which works by preventing virions from attach-
ing to host cells (Pevear et al., 1999; Chen et al., 2008). Pleconaril
was found to be an effective antiviral compound against CVB
strains having isoleucine or valine at position 1092 in the VP1
region, whereas leucine at this position was associated with
resistance (Schmidtke et al., 2005).
More recently, novel antiviral candidates have been designed
against CVB, and EVs in general, by taking advantage of new
discoveries regarding virion morphogenesis. Glutathione (GSH),
the most prevalent non-protein thiol in the animal cell, was
identiﬁed as an essential stabilizing cofactor during virion particle
formation (Thibaut et al., 2014). A newly discovered inhibitor,
TP219, binds GSH and depletes intracellular stores, thereby inter-
fering with virus assembly but not RNA replication. Additional
antiviral candidates, such as 1, 2-ﬂuoro-4-(2-methyl-8-(3-(methyl-
sulfonyl) benzylamino) imidazo(1,2-a)pyrazin-3-yl)phenol, have
been developed which directly inhibit phosphatidylinositol
4-kinase, an enzyme essential for EV replication (van der Schaar
et al., 2013). Also, Itraconazole has been identiﬁed as a broad-
spectrum inhibitor of EVs by interfering with oxysterol-binding
protein (OSBP) and OSBP-related protein 4 functions (Strating
et al., 2015). Knockdown of these proteins has been shown to
inhibit EV replication by preventing the shuttling of cholesterol
and phosphatidylinositol-4-phoshpate between membranes dur-
ing the formation of viral replication organelles.
Fluoxetine, a selective serotonin reuptake inhibitor, was identi-
ﬁed through screening of small molecule libraries as an effective
inhibitor of EV replication (Zuo et al., 2012). Also, Fluoxetine may
show efﬁcacy during a persistent infection, and this antiviral
molecule was recently demonstrated to “cure” human pancreatic
cells infected in culture with CVB (Alidjinou et al., 2015). The
mechanism of action remains unclear, and utilizing ﬂuoxetine as
an antiviral may be problematic based on its neurological effects
on serotonin uptake and involvement with an increased risk of
bleeding when given with inhibitors of platelet function
(Alderman et al., 1992). We can expect some antiviral drugs to
have greater efﬁcacy or side effects based on genetic differences
between individuals. The concept of host molecular proﬁling and
personalized medicine to treat medical illnesses, including viral
infections, will be a critical ﬁeld in the future (Law et al., 2013).
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With the advent of induced pluripotent stem cells (iPSCs) and the
generation of cardiomyocytes derived from iPSCs, the efﬁcacy of
antiviral compounds and CVB-induced viral myocarditis can be
quantitatively assessed on patient-derived cardiomyocytes
(Sharma et al., 2014).
Cleavage of host proteins by CVB proteases
In addition to host proteins required for autophagy and the
host antiviral response, CVB has been shown to cleave dystrophin,
a vital protein in the heart which supports muscle ﬁber strength
(Badorff et al., 2000). Cleavage of dystrophin by CVB viral 2A
protease following infection is thought to contribute to dilated
cardiomyopathy following infection (Badorff et al., 1999). Trans-
genic mice were generated replacing the dystrophin gene with a
variant gene no longer containing a CVB viral 2A protease cleavage
site. These transgenic mice showed reduced cardiac virus titers
following infection and did not suffer from dilated cardiomyo-
pathy normally induced by cardiomyocyte-restricted expression of
the CVB viral 2A protease (Lim et al., 2013).
The targeting of multiple host proteins by CVB viral proteases
demonstrates the incredible ability of RNA viruses of limited size
to engineer proteins serving multiple functions during replication.
Nevertheless, the precise targeting of host proteins and evasion of
the host antiviral immune response by viral proteases necessary to
maximize viral replication and dissemination might also restrict
the ability of CVB, and other EVs, to form a diverse quasispecies
cloud to quickly adapt to new environments. The design of
inhibitors against CVB proteases might provide an opportunity to
limit viral replication and reduce virus-associated pathology. A
soluble inhibitor of CVB 3C protease was shown to prevent
cardiomyopathy following infection (Lim et al., 2014).
CVB RNA persistence and chronic disease
Intriguingly, persistent CVB infections have been linked to
autoimmune-type diseases such as chronic myocarditis
(Chapman and Kim, 2008), diabetes (Sane et al., 2011), and chronic
inﬂammatory myopathy (Tam et al., 2003). Virus persistence in
target tissues is associated with chronic disease, although the
mechanism of persistence is not clear and may involve the
continued presence of viral RNA rather than active virus replica-
tion. Nevertheless, the presence of replication-restricted viral RNA
has been shown to contribute to the disease process possibly
following the production of viral proteinases or induction of innate
immunity against the viral genome (Wessely et al., 1998). Numer-
ous studies suggest that persistent viruses, especially those such as
CVB, may provide chronic inﬂammatory events whereby auto-
reactive T cells become stimulated and secrete inﬂammatory
cytokines through a variety of potential mechanisms, including
molecular mimicry and bystander activation (Oldstone, 1998;
Horwitz et al., 1998). It is not clear what effect persistent infection
and the associated inﬂammatory events might have on resident
progenitor cells, either during development, or in the adult.
Some studies have suggested that the lack of infectious virus
during the persistent stage of infection indicates that CVB-
associated diseases, which include myocarditis, occur through
autoimmune mechanisms. However in a recent study, myocarditis
failed to appear in mice lacking CAR expression speciﬁcally on
cardiomyocytes – suggesting myocarditis requires that cardiomyo-
cytes become infected (Shi et al., 2009). Since other tissues, such as
the pancreas, were readily infected in their model, putative
autoreactive T cells against cardiac proteins could have been
produced yet failed to appear. These results cast doubt on the
notion that CVB infection induces a cross-reactive immune
response against cardiac proteins. Rather direct viral infection
causing cellular damage and the accompanying virus-mediated
immune response greatly contribute to the disease process in
infected cardiac tissue.
Few have considered the possibility that RNA viruses may
establish a “latent” infection with periodic reactivation – more
commonly observed for retroviruses or for DNA viruses in the
Herpesviridae family (Feuer et al., 2009; Feuer and Whitton, 2008).
We previously published studies suggesting that CVB remains in a
“latent” state in quiescent tissue culture cells (Feuer et al., 2004,
2002). Also, CVB readily establishes a carrier-state infection in cells
grown in culture, including HL-1 cells and NPCs continuously
passaged in culture (Pinkert et al., 2011; Tsueng et al., 2011, 2015).
We hypothesize that neurogenic regions of the CNS may support
CVB persistent infection, and virus reactivation may result upon
intermittent progenitor cell expansion and proliferation (Rhoades
et al., 2011).
Viruses with RNA-based genomes tend to be less stable,
although some RNA viruses may have developed sophisticated
stabilization strategies by limiting RNA decay (Iwakawa et al.,
2008) or forming double-stranded RNA complexes (Tam and
Messner, 1999). The molecular mechanism of CVB persistence
with restricted viral replication in the heart and pancreas may
involve the generation of non-cytolytic variants harboring 50
terminal mutations and deletions (Lee et al., 2005; Kim et al.,
2005; Chapman and Kim, 2008; Chapman et al., 2008; Tracy et al.,
2015). The sporadic expression of viral proteins during CVB
persistence in the absence of signiﬁcant viral replication may
nevertheless lead to a chronic immune response and immuno-
pathology (Whitton and Feuer, 2004).
Recent studies have shown the clinical dangers of suppressing
the humoral immune response with anti-CD20 monoclonal anti-
bodies such as rituximab. Treatment with rituximab is routinely
given to patients suffering from lymphomas, leukemias, transplant
rejection and some autoimmune disorders. However, case reports
describing EV meningoencephalitis following treatment with
rituximab have been increasing in number (Servais et al., 2010;
Schilthuizen et al., 2010). B cell-dependent immunosuppression
following the administration rituximab as a therapy for lympho-
mas or leukemias would naturally reduce the level of circulating
anti-CVB antibodies. If these protective antibodies suppress CVB
replication in target tissues such as the CNS harboring persistent
viral RNA, meningoencephalitis might be the outcome for some
patients (Kiani-Alikhan et al., 2009).
Conclusions and future perspectives
Although recent discoveries have been made regarding deter-
minants of CVB tropism, host proteins involved in CVB replication
in target cells, and mechanisms of CVB pathogenesis; many
questions remain unanswered. Also, newer and more speciﬁc
antiviral therapies need to be pursued in order to provide a
catalog of treatment strategies to control both acute and persistent
infection. With the advent of stem cell therapy, questions remain if
the administration of progenitor cells in tissues harboring persis-
tent infectious agents such as CVB might provide new target cells
thereby limiting potential success of tissue regeneration, including
in the compromised heart. In addition, can new treatment strate-
gies be devised to control chronic inﬂammatory response or
reactivation during persistent CVB infection? What are the lasting
effects of CVB infection on the host, particularly following the
infection and recovery of progenitor cells? CVB clearly utilizes
autophagy to replicate, but also simultaneously commandeers host
proteins such as GBF1, Arf1, and PI4KIIIβ to construct viral
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replication organelles. How can studies describing induction of
autophagy and the formation of virus replication organelles be
uniﬁed in order to fully comprehend CVB replication within the
host cell (Jackson, 2014)?
Is there an inherent need for CVB to access the autophagy
pathway to complete the necessary steps of viral replication – such
as for virion maturation? Although CVB titers are greatly reduced
in culture when inhibiting the autophagy pathway (Wong et al.,
2008b), or upon infection of mice lacking ATG5 (Alirezaei et al.,
2012b), viral replication can still proceed – suggesting that a strict
requirement for autophagy is not an absolute necessity. Alterna-
tively, perhaps CVB evolved to utilize autophagy for a greater
beneﬁt – such as for the fabrication of camouﬂage vesicles
engineered to remain within host cells for a longer period, and
for the construction of escape pods to eventually leave host cells
(Richards and Jackson, 2013). Can new therapies against CVB be
designed based on personalized medicine and having limited
toxicity/side effects? Can novel antiviral drugs be identiﬁed that
target the formation of viral replication complexes or hinder virus-
induced autophagy activation? What are the molecular factors
that might assist CVB-associated EMVs to enter new target cells?
Do CVB-associated EMVs broaden viral tropism within the host?
Hence, more research is needed to better understand the mechan-
isms of CVB-mediated disease in the host and devising the best
treatment strategies for patients.
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